Formenti, Silvia C. http://orcid.org/0000-0002-8227-8924
Rudqvist, Nils-Petter http://orcid.org/0000-0002-9720-3124
Golden, Encouse
Cooper, Benjamin
Wennerberg, Erik
Lhuillier, Claire
Vanpouille-Box, Claire http://orcid.org/0000-0001-7213-0670
Friedman, Kent
Ferrari de Andrade, Lucas
Wucherpfennig, Kai W.
Heguy, Adriana
Imai, Naoko
Gnjatic, Sacha http://orcid.org/0000-0001-5643-9520
Emerson, Ryan O.
Zhou, Xi Kathy http://orcid.org/0000-0002-8942-439X
Zhang, Tuo http://orcid.org/0000-0001-5396-918X
Chachoua, Abraham
Demaria, Sandra http://orcid.org/0000-0003-4426-0499
Article History
Received: 9 April 2018
Accepted: 4 September 2018
First Online: 5 November 2018
Competing interests
: Bristol Meyer Squibb did not have any role in the design, data collection and analysis, interpretation of results and preparation of the manuscript. Potential conflicts of interest: Full-time employment and equity ownership at Adaptive Biotechnologies Corporation (R.O.E.). Prior honorarium for consulting from Third Rock Ventures/Neon Therapeutics, B4CC, OncoMed, Merck, and research funding from Agenus, Bristol Meyer Squibb, Genentech, Pfizer, Janssen R&D, Immune Design (S.G.). Service on Scientific Advisory Board of Lytix Biopharma, prior honorarium for consulting/speaker from AstraZeneca, AbbVie Inc., Cytune Pharma, EMD Serono, Eisai Inc., Regeneron, Ventana Medical Systems, Inc. Research grants from Nanobiotix, and Lytix Biopharma (S.D.). Prior honorarium for consulting/speaker from Sanofi, AstraZeneca, Merck, Regeneron, Bayer, Serono/Merck, and research funding from Janssen R&D, Varian, Merck, Bristol Meyer Squibb (for a different study) (S.C.F.). Service on Scientific Advisory Board of Nextech, T-scan and TCR2, consultancy for Novartis, research funding from Astellas, Bristol-Myers Squibb and Novartis (not related to the topic of this mansucript) (K.W.W.).